Surgical treatment of primary and advanced gastrointestinal stromal tumours (GIST);Chirurgie des tumeurs stromales gastro-intestinales (GIST) aux stades localisés et métastatiques

Oncologie

Volumn 9, Issue 2, 2007, Pages 102-106

  Bonvalot, S ^a   Rouquie D ^a   Vanel, D ^a   Domont, J ^a   Le Cesne, A ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Gastrointestinal stromal tumour; GIST; Imatinib; Sarcoma; Surgery

Indexed keywords

IMATINIB;

ADJUVANT THERAPY; ADVANCED CANCER; ARTICLE; BLEEDING; CANCER GROWTH; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LAPAROSCOPY; LIVER METASTASIS; LYMPHADENECTOMY; METASTASIS; MITOSIS INDEX; POSTOPERATIVE COMPLICATION; SARCOMA; TUMOR BIOPSY; TUMOR NECROSIS; TUMOR VOLUME;

EID: 34247525574     PISSN: 12923818     EISSN: 17652839     Source Type: Journal    
DOI: 10.1007/s10269-006-0548-2     Document Type: Article

References (27)

1. Mazur MT, Clark HB (1983) Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 6: 507-19
2. Miettinen M, El-Rifai W, Sobin LH, et al. (2002) Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 33: 478-83
3. Blay JY, Landi B, Bonvalot S, et al. (2005) Recommendations for the managment of GIST patients. Bull Cancer 10: 907-18
4. De Matteo RP, Lewis JJ, Leung D, et al. (2000) Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 1: 51-8
5. Blay JY, Bonvalot S, Casali P, et al. (2005) Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 4: 566-78. Erratum in Ann Oncol 2005; 6: 993
6. Aparicio T, Boige V, Sabourin JC, et al. (2004) Prognostic factors after surgery of primary resectable gastrointestinal stromal tumours. Eur J Surg Oncol 10: 1098-103
7. Ng EH, Pollock RE, Munsell MF, et al. (1992) Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 1: 68-77
8. Known SJ (2001) Korean gastric study cancer group. Surgery and prognostic factors for gastric stromal tumor. World J Surg 3: 290-5
9. Clary BM, De Matteo RP, Lewis JJ, et al. (2001) Gastrointestinal stromal tumors and leiomyosarcoma of the abdomen and retroperitoneum: a clinical comparison. Ann Surg Oncol 4: 290-9
10. Kosmadakis N, Visvardis EE, Kartsaklis P, et al. (2005) The role of surgery in the management of gastrointestinal stromal tumors (GISTs) in the era of imatinib mesylate effectiveness. Surg Oncol 14: 75-84
11. Pierie JP, Choudry U, Muzikanski A, et al. (2001) The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg 4: 383-9
12. Fletcher CD, Berman JJ, Corless C, et al. (2002) Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 5: 459-65
13. Van der Zwan SM, DeMatteo RP (2005) Gastrointestinal stromal tumor: 5-years later. Cancer 9: 1781-8
14. Plaat BE, Hollema H, Molenaar WM, et al. (2000) Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol 18: 3211-20
15. Mudan SS, Conlon KC, Woodruff JM, et al. (2000) Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patients selection. Cancer 1: 66-74
16. Rutkowski P, Nyckowski P, Grzesiakowska U, et al. (2003) The clinical characteristics and the role of surgery and imatinib treatment in patients with liver metastases from c-Kit positive gastrointestinal stromal tumors (GIST). Neoplasma 6: 438-42
17. Jaques DP, Coit DG, Casper ES, et al. (1995) Hepatic metastases from soft-tissue sarcoma. Ann Surg 4: 392-7
18. DeMatteo RP, Shah A, Fong Y, et al. (2001) Results of hepatic resection for sarcoma metastatic to liver. Ann Surg 4: 540-7
19. e Congrés de l'AFC. Monographie de l'Association française de chirurgie. Éditions Arnette
20. Bonvalot S, Cavalcanti A, Le Pechoux C, et al. (2005) Randomized trial of cytoreduction followed by intraperitoneal chemotherapy versus cytoreduction alone in patients with peritoneal sarcomatosis. Eur J Surg Oncol 8: 917-23
21. Verweij J, Van Oosterom A, Blay JY, et al. (2003) Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 14: 2006-11
22. Demetri GD, Von Mehren M, Blanke CD, et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 7: 472-80
23. Verweij J, Casali PG, Zalcberg J, et al. (2004) Progression-free survival in gastrointestinal stromal tumors with highdose imatinib: randomized trial. Lancet 9440: 1127-34
24. Zalcberg JR, Verweij J, Casali PG, et al. (2005) EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group; Australasian Gastrointestinal Trials Group. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 12: 1751-7
25. Scaife CL, Hunt KK, Patel SR, et al. (2003) Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate? Am J Surg 6: 665-9
26. Bonvalot S, Eldweny H, Le Péchoux C, et al. (2006) Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann Surg Oncol, Sept 6
27. Benjamin RS, Blanke CD, Blay JY, et al. (2006) Management of gastro intestinal stromal tumors in the imatinib era: selected cases studies. Oncologist 1: 9-20